These results may be conducive to risk stratification and therapy decisions in pediatric patients with AML, and EVI1 transcript levels should be routinely assessed at diagnosis for risk stratification once a standard laboratory protocol is established and the cutoff value is determined. This evidence concerns the gene MECOM and acute myeloid leukemia.